SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

BriaPro Therapeutics, a subsidiary of BriaCell, has developed novel high-affinity antibodies targeting B7-H3, a protein overexpressed in multiple solid tumors while showing limited expression in normal tissues.

BriaCell Therapeutics will present data from three clinical studies at the 2025 AACR Annual Meeting, including results from its pivotal Phase 3 trial of Bria-IMT in metastatic breast cancer.

The independent Data Safety Monitoring Board has completed its second safety review of BriaCell's pivotal Phase 3 study, finding no safety concerns and recommending continuation without modifications.

BriaCell Therapeutics plans to raise US$5.5 million through a public share offering of common shares and warrants.